Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.
ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.
ANI Pharmaceuticals announced the acquisition of Fluconazole Tablets USP from a private company for $3.0 million. The product's current annual U.S. market is valued at approximately $40 million, indicating significant market opportunity. Interim President and CEO Patrick Walsh expressed enthusiasm for integrating this product into ANI's portfolio, which is expected to enhance margins and competitive positioning. Fluconazole Tablets are used primarily for treating vaginal and esophageal candidiasis, among other conditions.
ANI Pharmaceuticals announced the launch of Mexiletine Hydrochloride Capsules USP, available in 150mg, 200mg, and 250mg dosages, targeting a $16 million U.S. market. This marks ANI's sixth generic product launch in 2020 and the first from its Oakville, Canada site, which was acquired in August 2018. Mexiletine is indicated for treating life-threatening ventricular arrhythmias. The company's Interim President and CEO, Patrick Walsh, emphasized the milestone's importance for future product development.